To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:81452
Name large B-cell lymphoma
Definition A B-cell lymphoma that is characterized by large lymphoid cells of the B-cell lineage that by definition form sheets or clusters.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma B-cell lymphoma large B-cell lymphoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT05852717 Phase II Cisplatin + Dexamethasone + Epcoritamab-bysp + Gemcitabine Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma Recruiting USA 0
NCT06050694 Phase II Cyclophosphamide + Doxorubicin + Glofitamab-gxbm + Polatuzumab vedotin-piiq + Prednisone + Rituximab Cyclophosphamide + Doxorubicin + Polatuzumab vedotin-piiq + Prednisone + Rituximab Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL) (GRAIL) Not yet recruiting CAN 0
NCT06071871 Phase II Glofitamab-gxbm + Obinutuzumab + Polatuzumab vedotin-piiq A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab as a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma (PORTAL) Recruiting GBR 0
NCT06248086 Phase I ASP101G + ASP2802 A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas Terminated AUS 0
NCT06486051 Phase II Cyclophosphamide + Fludarabine WZTL-002 A Study of WZTL-002 CAR T-cells for Adults With Relapsed Large B-cell Lymphoma (ENABLE-2) Recruiting NZL 0
NCT06500273 Phase II ALLO-501A ALLO-647 + Cyclophosphamide + Fludarabine Cyclophosphamide + Fludarabine Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL (ALPHA3) Recruiting USA 0
NCT06528301 Phase I UB-VV111 Sirolimus + UB-VV111 A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies Recruiting USA | AUS 0
NCT06536049 Phase Ib/II Epcoritamab-bysp + Ibrutinib Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma Recruiting USA 0
NCT06542250 Phase Ib/II AZD5492 A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies. (TITANium) Recruiting USA | ITA | FRA | ESP | DNK | DEU | CAN | AUS 2
NCT06564038 Phase Ib/II Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + TNB-486 + Vincristine Sulfate Acalabrutinib + TNB-486 TNB-486 A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies (Soundtrack-E) Recruiting USA | GBR | FRA | ESP | DNK | DEU | CZE | AUS 4
NCT06594939 Phase II Cyclophosphamide + Doxorubicin + Mosunetuzumab-axgb + Polatuzumab vedotin-piiq + Prednisone Pegfilgrastim Cyclophosphamide + Doxorubicin + Mosunetuzumab-axgb + Prednisone Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma Not yet recruiting USA 0
NCT06723457 Phase II Epcoritamab-bysp + Lenalidomide Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma Not yet recruiting USA 0
NCT06730542 Phase I Cyclophosphamide + Doxorubicin + Methotrexate + Polatuzumab vedotin-piiq + Prednisone + Rituximab + Zanubrutinib Zanubrutinib in Combination with Pola-R-CHP and High-dose Methotrexate in Patients with Secondary CNS Lymphoma Recruiting USA 0
NCT06760156 Phase II Lenalidomide + Tafasitamab-cxix Phase 2 Study of Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym Recruiting USA 0
NCT06784726 Phase II Odronextamab Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T Not yet recruiting USA 0
NCT06811272 Phase II Epcoritamab-bysp Dexamethasone + Epcoritamab-bysp Outpatient Epcoritamab As 2L in NTE R/R DLBCL Not yet recruiting USA 0
NCT06834373 Phase II CC-99282 + Rituximab Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy Not yet recruiting USA 0